Related Experiment Video

Updated: Aug 2, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

[Clinical evaluation of a new oral cephalosporin, cefprozil, in pediatrics]

M Woo1, H Higashino, U Kohdera

  • 1Department of Pediatrics, Kansai Medical University.

The Japanese Journal of Antibiotics
|December 1, 1992
PubMed

Insights

Cefprozil (CFPZ) is a new oral cephalosporin antibiotic demonstrating 100% clinical efficacy in pediatric patients with various bacterial infections. It showed stronger antibacterial activity than cefaclor and was well-tolerated.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Pediatrics

Background:

  • Cefprozil (CFPZ) is a novel oral cephalosporin antibiotic.
  • Evaluation of antibacterial activity and clinical efficacy is crucial for new antimicrobial agents.

Purpose of the Study:

  • To assess the antibacterial activity and clinical efficacy of Cefprozil (CFPZ).
  • To determine the safety and tolerability of Cefprozil (CFPZ) in pediatric patients.

Main Methods:

  • A clinical study involving 34 pediatric patients treated with Cefprozil (CFPZ) at doses of 7.7-36.2 mg/kg/day in three divided doses.
  • Evaluation of clinical efficacy in 33 patients across various infections including pneumonia, bronchitis, upper respiratory tract infections, urinary tract infections, lymphadenitis, and soft tissue infections.
  • Bacteriological response was assessed for identified strains.

Main Results:

  • Overall clinical efficacy rate was 100% (8 excellent, 23 good) among evaluable patients.
  • Bacteriological eradication was confirmed in 66.7% (6/9) of identified bacterial strains.
  • Cefprozil (CFPZ) exhibited superior antibacterial activity compared to cefaclor.
  • Adverse events were minimal, observed in only 2 patients (nausea, pallor, increased eosinophils).

Conclusions:

  • Cefprozil (CFPZ) is a safe and effective oral antibiotic for treating bacterial infections in pediatric patients.
  • The drug demonstrates promising antibacterial potency and a favorable safety profile.

More Related Videos

Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates08:32

Assessment of Intestinal Transcytosis of Neonatal Escherichia coli Bacteremia Isolates

Published on: February 17, 2023

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

Related Concept Videos

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...